| Glenwood Care And Rehabilitation | |
| 836 West 34th Street Nw, Canton, Ohio 44709 | |
| (330) 492-7131 | |
| Name | Glenwood Care And Rehabilitation |
|---|---|
| Location | 836 West 34th Street Nw, Canton, Ohio |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 99 |
| Occupancy Rate | 80.4% |
| Medicare ID (CCN) | 366095 |
| Legal Business Name | Stone Crossing Skilled Care Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1316247976 |
| Organization Name | STONE CROSSING MANAGEMENT, LLC |
| Address | 836 34th St Nw, Canton, OH 44709 |
| Phone Number | 330-492-7131 |
News Archive
Furiex Pharmaceuticals, Inc. announced today that it has acquired full exclusive license rights to develop and commercialize the compound JNJ-Q2 under its existing development and license agreement with Janssen Pharmaceutica N.V.. Furiex acquired these rights as a result of Janssen's decision not to exercise its option under the agreement that gave Janssen the opportunity to continue development of JNJ-Q2.
A fifty-fold between-country difference in rates of paracetamol-induced acute liver failure that leads to liver transplant (ALFT) has been revealed by a study that compared patient data from seven countries at the request of the European Medicines Agency: France, Greece, Ireland, Italy, Netherlands, Portugal and the UK.
Heavy smoking in midlife is associated with a 157 percent increased risk of developing Alzheimer's disease and a 172 percent increased risk of developing vascular dementia, according to a Kaiser Permanente study published in the Archives of Internal Medicine.
A new research program has been launched to produce all the human secreted proteins in mammalian cell factories. The program aims to facilitate studies of this important class of proteins, which are involved in many human diseases.
Delcath Systems, Inc. a development stage, specialty pharmaceutical and medical device company focused on oncology will host a conference call to discuss recent corporate developments on Tuesday, June 15, 2010 at 4:30 p.m., Eastern. Eamonn P. Hobbs, the Company's President and CEO, David McDonald, CFO, and Krishna Kandarpa, MD, Chief Medical Officer, will be on hand during the call and webcast.
› Verified 4 days ago
| NPI Number | 1417224874 |
| Organization Name | LL CANTON, LLC |
| Doing Business As | STONE CROSSING CARE CENTER BY LAMPLIGHT COMMUNICATIONS |
| Address | 836 34th St Nw, Canton, OH 44709 |
| Phone Number | 330-492-7131 |
News Archive
Furiex Pharmaceuticals, Inc. announced today that it has acquired full exclusive license rights to develop and commercialize the compound JNJ-Q2 under its existing development and license agreement with Janssen Pharmaceutica N.V.. Furiex acquired these rights as a result of Janssen's decision not to exercise its option under the agreement that gave Janssen the opportunity to continue development of JNJ-Q2.
A fifty-fold between-country difference in rates of paracetamol-induced acute liver failure that leads to liver transplant (ALFT) has been revealed by a study that compared patient data from seven countries at the request of the European Medicines Agency: France, Greece, Ireland, Italy, Netherlands, Portugal and the UK.
Heavy smoking in midlife is associated with a 157 percent increased risk of developing Alzheimer's disease and a 172 percent increased risk of developing vascular dementia, according to a Kaiser Permanente study published in the Archives of Internal Medicine.
A new research program has been launched to produce all the human secreted proteins in mammalian cell factories. The program aims to facilitate studies of this important class of proteins, which are involved in many human diseases.
Delcath Systems, Inc. a development stage, specialty pharmaceutical and medical device company focused on oncology will host a conference call to discuss recent corporate developments on Tuesday, June 15, 2010 at 4:30 p.m., Eastern. Eamonn P. Hobbs, the Company's President and CEO, David McDonald, CFO, and Krishna Kandarpa, MD, Chief Medical Officer, will be on hand during the call and webcast.
› Verified 4 days ago
| NPI Number | 1629264379 |
| Organization Name | PEREGRINE SERVICES OF CANTON, LLC |
| Doing Business As | SUMMIT'STRACE OF CANTON |
| Address | 836 34th St Nw, Canton, OH 44709 |
| Phone Number | 614-459-2482 |
News Archive
Furiex Pharmaceuticals, Inc. announced today that it has acquired full exclusive license rights to develop and commercialize the compound JNJ-Q2 under its existing development and license agreement with Janssen Pharmaceutica N.V.. Furiex acquired these rights as a result of Janssen's decision not to exercise its option under the agreement that gave Janssen the opportunity to continue development of JNJ-Q2.
A fifty-fold between-country difference in rates of paracetamol-induced acute liver failure that leads to liver transplant (ALFT) has been revealed by a study that compared patient data from seven countries at the request of the European Medicines Agency: France, Greece, Ireland, Italy, Netherlands, Portugal and the UK.
Heavy smoking in midlife is associated with a 157 percent increased risk of developing Alzheimer's disease and a 172 percent increased risk of developing vascular dementia, according to a Kaiser Permanente study published in the Archives of Internal Medicine.
A new research program has been launched to produce all the human secreted proteins in mammalian cell factories. The program aims to facilitate studies of this important class of proteins, which are involved in many human diseases.
Delcath Systems, Inc. a development stage, specialty pharmaceutical and medical device company focused on oncology will host a conference call to discuss recent corporate developments on Tuesday, June 15, 2010 at 4:30 p.m., Eastern. Eamonn P. Hobbs, the Company's President and CEO, David McDonald, CFO, and Krishna Kandarpa, MD, Chief Medical Officer, will be on hand during the call and webcast.
› Verified 4 days ago
| NPI Number | 1912979477 |
| Organization Name | THE SCHROER GROUP, INC. |
| Address | 836 34th St Nw, Canton, OH 44709 |
| Phone Number | 330-492-7131 |
News Archive
Furiex Pharmaceuticals, Inc. announced today that it has acquired full exclusive license rights to develop and commercialize the compound JNJ-Q2 under its existing development and license agreement with Janssen Pharmaceutica N.V.. Furiex acquired these rights as a result of Janssen's decision not to exercise its option under the agreement that gave Janssen the opportunity to continue development of JNJ-Q2.
A fifty-fold between-country difference in rates of paracetamol-induced acute liver failure that leads to liver transplant (ALFT) has been revealed by a study that compared patient data from seven countries at the request of the European Medicines Agency: France, Greece, Ireland, Italy, Netherlands, Portugal and the UK.
Heavy smoking in midlife is associated with a 157 percent increased risk of developing Alzheimer's disease and a 172 percent increased risk of developing vascular dementia, according to a Kaiser Permanente study published in the Archives of Internal Medicine.
A new research program has been launched to produce all the human secreted proteins in mammalian cell factories. The program aims to facilitate studies of this important class of proteins, which are involved in many human diseases.
Delcath Systems, Inc. a development stage, specialty pharmaceutical and medical device company focused on oncology will host a conference call to discuss recent corporate developments on Tuesday, June 15, 2010 at 4:30 p.m., Eastern. Eamonn P. Hobbs, the Company's President and CEO, David McDonald, CFO, and Krishna Kandarpa, MD, Chief Medical Officer, will be on hand during the call and webcast.
› Verified 4 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Furiex Pharmaceuticals, Inc. announced today that it has acquired full exclusive license rights to develop and commercialize the compound JNJ-Q2 under its existing development and license agreement with Janssen Pharmaceutica N.V.. Furiex acquired these rights as a result of Janssen's decision not to exercise its option under the agreement that gave Janssen the opportunity to continue development of JNJ-Q2.
A fifty-fold between-country difference in rates of paracetamol-induced acute liver failure that leads to liver transplant (ALFT) has been revealed by a study that compared patient data from seven countries at the request of the European Medicines Agency: France, Greece, Ireland, Italy, Netherlands, Portugal and the UK.
Heavy smoking in midlife is associated with a 157 percent increased risk of developing Alzheimer's disease and a 172 percent increased risk of developing vascular dementia, according to a Kaiser Permanente study published in the Archives of Internal Medicine.
A new research program has been launched to produce all the human secreted proteins in mammalian cell factories. The program aims to facilitate studies of this important class of proteins, which are involved in many human diseases.
Delcath Systems, Inc. a development stage, specialty pharmaceutical and medical device company focused on oncology will host a conference call to discuss recent corporate developments on Tuesday, June 15, 2010 at 4:30 p.m., Eastern. Eamonn P. Hobbs, the Company's President and CEO, David McDonald, CFO, and Krishna Kandarpa, MD, Chief Medical Officer, will be on hand during the call and webcast.
› Verified 4 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $11700 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 16.61 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 10.22 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 28.03 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.93 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 5.57 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 8.45 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 2.62 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 82.95 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 10.31 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 43.48 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 12.15 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 38.69 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 14.36 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 95.71 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 56.83 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 52.05 | 82.93 |
News Archive
Furiex Pharmaceuticals, Inc. announced today that it has acquired full exclusive license rights to develop and commercialize the compound JNJ-Q2 under its existing development and license agreement with Janssen Pharmaceutica N.V.. Furiex acquired these rights as a result of Janssen's decision not to exercise its option under the agreement that gave Janssen the opportunity to continue development of JNJ-Q2.
A fifty-fold between-country difference in rates of paracetamol-induced acute liver failure that leads to liver transplant (ALFT) has been revealed by a study that compared patient data from seven countries at the request of the European Medicines Agency: France, Greece, Ireland, Italy, Netherlands, Portugal and the UK.
Heavy smoking in midlife is associated with a 157 percent increased risk of developing Alzheimer's disease and a 172 percent increased risk of developing vascular dementia, according to a Kaiser Permanente study published in the Archives of Internal Medicine.
A new research program has been launched to produce all the human secreted proteins in mammalian cell factories. The program aims to facilitate studies of this important class of proteins, which are involved in many human diseases.
Delcath Systems, Inc. a development stage, specialty pharmaceutical and medical device company focused on oncology will host a conference call to discuss recent corporate developments on Tuesday, June 15, 2010 at 4:30 p.m., Eastern. Eamonn P. Hobbs, the Company's President and CEO, David McDonald, CFO, and Krishna Kandarpa, MD, Chief Medical Officer, will be on hand during the call and webcast.
› Verified 4 days ago
Hall Of Fame Rehabilitation And Nursing Center Location: 2714 13th Street Nw, Canton, Ohio 44708 Phone: (330) 456-2842 | |
Mckinley Health Care Ctr Llc Location: 800 Market Avenue North, Canton, Ohio 44702 Phone: (330) 456-1014 | |
Aultman Transitional Care Center Location: 2821 Woodlawn Avenue Nw, Canton, Ohio 44708 Phone: (330) 479-4800 | |
Glenwood Care And Rehabilitation Location: 836 West 34th Street Nw, Canton, Ohio 44709 Phone: (330) 492-7131 |